Your session is about to expire
← Back to Search
BI 836845 for Prostate Cancer
Study Summary
This trial is testing a new drug to see if it's safe and effective against prostate cancer. The trial has three parts: first they test how well the drug works and how safe it is, then they test it on people who are already taking another prostate cancer drug, and finally they compare the new drug to the other prostate cancer drug.
- Castration-resistant Prostate Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any vacancies available for prospective participants in this experiment?
"Unfortunately, recruitment has ended for this trial as the last update was on November 15th 2022. However, if you are still searching for a trial to take part in, over 1250 trials related to prostate cancer that is resistant to castration and 98 studies involving BI 836845 are currently seeking participants."
What is the size of the cohort engaging in this research?
"Unfortunately, this research project is no longer enrolling patients. It was initially posted on November 11th 2014 and its information was most recently edited on 15/11/2022. For those searching for alternative studies, there are currently 1252 trials accepting participants diagnosed with prostatic cancer resistant to castration treatments as well as 98 clinical experiments that accept participants being treated with BI 836845."
Is BI 836845 a safe and efficacious treatment for patients?
"Our assessment of the safety profile for BI 836845 is a 1, as this Phase 1 trial includes limited data regarding both efficacy and safety."
Could you provide an overview of the experiments which have already been conducted regarding BI 836845?
"BI 836845 was initially studied in 2005 at the Rosemere Cancer Centre located at Royal Preston Hospital. As of today, there have been 89 completed studies with 98 actively recruiting clinical trials; many of these are based out of New york City."
Share this study with friends
Copy Link
Messenger